Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for Cognitive Dysfunction in Acute Depression with Inflammation
NCT06136546Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2025
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of infliximab in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Started Jan 2025; status: recruiting.
02
Drugs
infliximab
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06136546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136546.